(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 May 2021 (27.05.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/102320 A1

(51) International Patent Classification:
A61K 39/02 (2006.01) *A61K 39/395* (2006.01)
A61K 39/08 (2006.01) *A61K 47/36* (2006.01)

(21) International Application Number:
PCT/US2020/061594

(22) International Filing Date:
20 November 2020 (20.11.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/939,331 22 November 2019 (22.11.2019) US
62/994,130 24 March 2020 (24.03.2020) US

(71) Applicant: **ONEBIOPHARMA, INC.** [US/US]; 124 Marlborough Street, Boston, MA 02111 (US).

(72) Inventors; and
(71) Applicants: **WYAND, Michael** [US/US]; 124 Marlborough Street, Boston, MA 02111 (US). **SWISS, Gerald, F.** [US/US]; 124 Marlborough Street, Boston, MA 02111 (US).

(74) Agent: **BEHAR, Victor** et al.; Mintz Levin Cohn Ferris Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) **Title:** METHODS FOR PROVIDING CONTINUOUS THERAPY AGAINST PNAG COMPRISING MICROBES

(57) **Abstract:** Disclosed are antimicrobial vaccines comprising oligosaccharide β-(1→6)-glucosamine groups.

WO 2021/102320 A1

METHODS FOR PROVIDING CONTINUOUS THERAPY AGAINST PNAG COMPRISING MICROBES

Cross-Reference to Related Applications

[0001] This application claims priority to U.S. provisional application nos. 62/939,331, filed on November 22, 2019, and 62/994,130, filed on March 24, 2020, which are incorporated herein by reference in their entireties.

Field of the Invention

[0002] This invention is directed to methods for providing continuous therapy against PNAG comprising microbes. In particular, these methods utilize a combination of a PNAG vaccine and a monoclonal antibody. The monoclonal antibody targets PNAG and provides for immediate therapy against such microbes whereas the PNAG vaccine generates an endogenous immune response that, once it becomes effective, complements the monoclonal antibody to the extent that the immune response generated by the vaccine provides an additional avenue of therapy provided by the antibody. The combination of these provides continuous therapy from the start of treatment.

State of the Art

[0003] The art has previously disclosed antimicrobial vaccines comprising oligosaccharide β-(1→6)-glucosamine groups where the number of repeating glucosamine units range as low as 1 and up to 300. One such example is provided in US Provisional Application No. 62/892,400, which is under petition to convert to non-provisional application and is incorporated herein by reference in its entirety.

[0004] The data generated to date show that these vaccines impart protective immunity against microbes comprising such oligosaccharide β-(1→6)-glucosamine structures including N-acetyl versions thereof in their cell wall. However, after inoculation, effective immunity begins about 4 or more weeks later in the treated patient. During this latent period, the patient is at risk of a microbial infection. This is particularly troublesome for patients already experiencing or at a significant risk of developing microbial infections during this latent period.

[0005] To treat patients requiring immediate protection against microbial infections, monoclonal antibodies were developed that target microbes whose cell walls comprise oligosaccharide N-acetyl-β-(1→6)-glucosamine structures. These monoclonal antibodies have demonstrated efficacy against such microbes and provide immediate antimicrobial protection after injection. One such monoclonal antibody is F-598 as disclosed in US Patent No. 7,786,255 which patent is incorporated herein by reference in its entirety. That antibody is recognized to bind to several N-acetylglucosamine groups of PNAG. The efficacy imparted by a single dose of this monoclonal antibody typically ranges up to about 4 or so weeks after injection.

[0006] However, there is a problem with treating patients who require immediate as well as long-term immune protection especially those patients who are experiencing microbial infections or who are at risk of such infections. These include elderly patients, burn patients, premature infants, patients undergoing chemotherapy or radiation therapy, and other related conditions. However, there is a concern that if the attending clinician administers the vaccine during the period of active protection provided by the monoclonal antibody, then at least a portion of the monoclonal antibody is at risk of cross-reacting to the oligosaccharide structures on the vaccine rendering both the vaccine as well as the monoclonal antibody either less effective or ineffective.

[0007] Hence, to avoid this problem, it would be necessary to ensure that the patient no longer has active immunity due to the presence of the monoclonal antibody prior to administering the vaccine. Moreover, given the inherent delay in the achieving effective immunity after vaccination, switching a patient from monoclonal antibody therapy to immune protection provided by vaccination requires a substantial incubation period where the patient is at risk of infection or whose infection is left to alternative and potentially less efficacious treatment methods. Because natural immunity arising from vaccination is more sustainable than that provided by the monoclonal antibody, the benefits of such natural immunity weigh heavily in favor of vaccination.

[0008] Accordingly, there is an ongoing need to provide for continuous immune protection to a patient when using both the monoclonal antibody as well as vaccination.

SUMMARY OF THE INVENTION

[0009] This invention is based on the discovery that the monoclonal antibody F-598 can serve as a complementary therapy to the vaccines disclosed herein for the treatment of PNAG-based microbes. Accordingly, this invention is directed to methods for providing continuous immune protection against PNAG based microbes by co-administration of a oligosaccharide β-(1→6)-glucosamine vaccine and F-598 monoclonal antibody. In one aspect, the vaccine is directed to a specific class of tetra-, penta-, and hexa-β-(1→6)-glucosamine–linked–tetanus toxoid vaccines that provide effective immunity to the patient against microbial infections wherein said microbe comprises PNAG structures in its cell walls.


[0010] Surprisingly, while these vaccines generate an endogenous immune response, the oligosaccharide β-(1→6)-glucosamine groups on the vaccine do not appreciably cross-react with the F-598 antibody. This surprising result allows for co-administration of both the vaccine and the antibody. Such co-administration further allows for the clinician to provide continuous complementary immune protection to the patient. In some embodiments, the complementary immune protection is synergistic.

[0011] Accordingly, in one embodiment, this invention provides for a method for providing continuous immune protection against PNAG microbes by use of a vaccine comprising a β-(1→6)-glucosamine oligosaccharide–linked–tetanus toxoid vaccine that provide effective immunity to a patient against microbial infections wherein said microbe comprises β-(1→6)-glucosamine structures in its cell walls. In one embodiment, the antibodies to the vaccine will bind to β-(1→6)-glucosamine structures. In some embodiments, said vaccine does not cross-react with a F-598 monoclonal antibody and further wherein said oligosaccharide comprises from 3 to 12 β-(1→6)-glucosamine units. In some embodiments, the vaccines generate antibodies that are complementary to F-598. That is where the vaccines disclosed herein will selectively bind to β-(1→6)-glucosamine structures, F-598 will selectively bind to acetylated β-(1→6)-glucosamine structures, *i.e.*, *N*-acetyl glucosamine.


[0012] In one embodiment, this invention provides for a vaccine against microbes comprising oligosaccharide β-(1→6)-glucosamine structures in their cell wall wherein said vaccine is represented by formula I:

$$(A\text{-}B)_x\text{-}C \quad I$$

where A comprises 3 to 12 β-(1→6)-glucosamine (carbohydrate ligand) groups or mixtures thereof wherein said oligosaccharide portion of the vaccine has the formula:



B is of the formula:



where A is as defined above and C is tetatus toxoid;


x is an integer from about 30 to about 39; and

y is an integer from 1 to 10.

[0013] In one embodiment, this invention provides for a vaccine against microbes comprising oligosaccharide β-(1→6)-glucosamine structures in their cell wall wherein said vaccine is represented by formula II:

$$(A'\text{-}B)_x\text{-}C \quad II$$

where A′ is a penta-β-(1→6)-glucosamine (carbohydrate ligand) group of the formula:




and B, C and *x* are as defined above.

[0014] In one embodiment, this invention provides for a pharmaceutical composition comprising a pharmaceutically acceptable diluent and an effective amount of the vaccine of formula I and/or formula II.

[0015] In one embodiment, this invention provides for a method for providing immunity to a patient from microbes comprising oligosaccharide β-(1→6)-glucosamine groups in their cell wall which method comprises administering said vaccine of formula I and/or formula II to said patient.

[0016] In one embodiment, this invention provides for a method for providing effective immunity to a patient from microbes comprising oligosaccharide β-(1→6)-glucosamine groups in their cell wall which method comprises administering the pharmaceutical composition of this invention to said patient.

[0017] Representative vaccines of this invention are set forth in the table below:



Example	Y	C	*x*
A	2	Tetanus toxoid	30-39

B	3	Tetanus toxoid	35-39
C	2	Tetanus toxoid	35-39
D	3	Tetanus toxoid	30-39
E	3	Tetanus toxoid	30-35
F	4	Tetanus toxoid	35-39
G	8	Tetanus toxoid	35-39
H	10	Tetanus toxoid	35-39

[0018] In embodiments, this invention provides a method for providing immunity to a patient from microbes comprising oligosaccharide β-(1→6)-glucosamine groups in their cell wall which method comprises administering said vaccine of formula I and/or formula II to said patient concurrently with a monoclonal antibody F-598.

[0019] "Concurrently," as used herein, can include before or during administration of said vaccine. In some embodiments, concurrent may include administration of the vaccine of formula I and/or formula II within about ±6 hours of administering F-598, or within ±4 hours, or within ±2 hours. In embodiments, the two can be administered as part of the same bolus injection. Administration is "concurrent" so long as the patient is able to mount immune response based on each individual components. The order in which F-598 and the vaccine of formula I or II are administered is not critical. Concurrent administration can correspond to any period of time outside of 2 or 6 hours and still be concurrent so long as both sets of antibodies (from F-598 and those generated from vaccine) are effectively providing antibody coverage for their respective targets for an overlapping period of time.

[0020] Without being bound by theory, the methods disclosed herein are complementary and synergistic because of the respective selectivities of the F-598 antibody and the antibodies generated from the vaccines of formulas I and II. It has been found that F-598 binds with specificity to N-acetyl rich regions of cell wall PNAG structures of microbes as described in "Structural basis for antibody targeting of the broadly expressed microbial polysaccharide poly-*N*-acetyl glucosamine," *J. Biol. Chem.*

293(14) 5079-5089 (2018), which is incorporated herein by reference in its entirety. The vaccines of formulas I and II, provide selectivity for non-*N*-acetylated regions of PNAG cell wall structures. In some embodiments, the presence of both populations of antibodies may minimize cross-reactivity and provide full protection against microbes having PNAG-bearing cell wall structures.

[0021] In some embodiments, F-598 is co-administered during the entire treatment period.

[0022] In some embodiments, F-598 is co-administered only up until a point where sufficient antibody titer is produced by the vaccines of formula I and/or formula II to effectively treat the patient. After the period in which there is such sufficient antibody produced by the vaccine, administration of F-598 may be terminated.

[0023] In some embodiments, F-598 may be terminated immediately after there is a measured sufficient titer of vaccine generated antibody. In embodiments, F-598 may be terminated one week after there is a measured sufficient titer of vaccine generated antibody. In embodiments, F-598 may be terminated two weeks after there is a measured sufficient titer of vaccine generated antibody. In embodiments, F-598 may be terminated one month after there is a measured sufficient titer of vaccine generated antibody. Those skilled in the art will appreciate that the exact period where it may be determined by the specific conditions/state of the patient.

[0024] In some embodiments, administering said vaccine of formula I and/or formula II may comprise a regimen of one to three administrations. For example, for some patients a single administration may be sufficient. For some patients two administrations may be needed. For some patients, three administrations may be needed. Among factors that may contribute to the number of administrations may be the age and condition of the patient. Very young patients with newly forming immune systems may require more than one administration. Similarly, elderly patients with immune systems in decline may require more than one administration.

[0025] In some embodiments, a treatment regimen includes monitoring of the patient for depletion of F-598 and/or the need for additional administrations of vaccine based on antibody titers. For example, a burn victim may require additional dosing of F-

598 due to secretion of antibody at the site of the wound. Accordingly, in some embodiments, the serum concentration of antibodies is evaluated periodically in order to maintain proper titer throughout the entire treatment regimen.

BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 illustrates the ^{1}H NMR for compound 17 (as described below).

[0027] Figure 2 illustrates the ^{13}C NMR for compound 17.

DETAILED DESCRIPTION OF THE INVENTION

[0028] This invention provides for antimicrobial vaccines comprising oligosaccharide β-(1→6)-glucosamine groups having from 3 to 12 glucosamine units linked to an immunogenic protein.

[0029] Prior to describing this invention in more detail, the following terms will first be defined. If a term used herein is not defined, it has its generally accepted scientific or medical meaning.

[0030] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.


[0031] "Optional" or "optionally" means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0032] The term "about" when used before a numerical designation, *e.g.*, temperature, time, amount, concentration, and such other, including a range, indicates approximations which may vary by (+) or (-) 10%, 5%, 1%, or any subrange or subvalue there between. Preferably, the term "about" when used with regard to a dose amount means that the dose may vary by +/- 10%.


[0033] "Comprising" or "comprises" is intended to mean that the compositions and methods include the recited elements, but not excluding others. "Consisting

essentially of" when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination for the stated purpose. Thus, a composition consisting essentially of the elements as defined herein would not exclude other materials or steps that do not materially affect the basic and novel characteristic(s) of the claimed invention. "Consisting of" shall mean excluding more than trace elements of other ingredients and substantial method steps. Embodiments defined by each of these transition terms are within the scope of this invention.


[0034] The term "β-(1→6)-glucosamine unit" or "glucosamine unit" refers to individual glucosamine structures as follows:



where the 6-hydroxyl group is condensed with the 1 hydroxyl group of the preceding glucosamine unit and where the dashed lines represent binding sites to the preceding and succeeding glucosamine units. When combined with another "β-(1→6)-glucosamine unit, the resulting disaccharide has the structure:



[0035] The term "β-(1→6)-glucosamine unit possessing an N-acetyl group refers to the structure:



where the 6-hydroxyl group of a second unit is condensed with the 1-hydroxyl group of the proceeding glucosamine unit as shown above albeit without the N-acetyl group.

[0036] The term "linker," as used herein, refers to any organic fragment that serves as a means to covalently connect the tetanus toxoid to the oligosaccharide domains disclosed herein. Any suitable linker known to one skilled in the art may be used, though generally such linkers will be selected to not be easily cleavable causing the separation of the oligosaccharide from its attachment to the toxoid structure. For example, the linker may be one of the linkers disclosed in U.S. Pat. No. 4,671,958; 4,867,973; 5,691,154; 5,846,728; 6,472,506; 6,541,669; 7,141,676; 7,176,185; or 7,232,805, each of which is incorporated herein by reference. Linkers may generally comprise C_2-C_{20} alkyene fragments with any number of interceding heteroatoms, especially nitrogen, sulfur, and oxygen. The carbon atoms may be substituted with alkyl, oxo, and the like. At the oligosaccharide reducing end the linker may be attached via N, O, or S linking at the anomeric center, though C-linking is also possible. At the toxoid end, the linker may be linked to a heteroatom on the toxoid. In some embodiments, the link is through amine functional groups of the toxoid. In some such embodiments, the linker is attached by forming an amide bond to the toxoid amino groups. The interceding atoms between the attachment point at the oligosaccharide end and the attachment point at the toxoid end is generally of little consequence, though it can be beneficial to have a structure that doesn't interfere with oligosaccharide antigenicity. In some embodiments, linkers may also be branched, thereby allowing more than one oligosaccharide to be attached per unit amino group on the toxoid via the linker.

[0037] The term "oligosaccharide comprising a "β-(1→6)-glucosamine group" refers to that group on the vaccine that mimics a portion of the cell wall that comprises oligosaccharides comprising "β-(1→6)-glucosamine structures" (as defined below).

[0038] The term "oligosaccharide comprising β-(1→6)-glucosamine structures" refer to those structures found in the cell wall of microbes. The microbial wall contains a large number of these structures that are conserved across many microbial lines. These structures are found in the microbial cell wall and include those oligosaccharides wherein the majority of their units are β-(1→6)-glucosamine.

[0039] The term "vaccine" as used herein refers to the ability of the compounds of this invention (formula I and II) to provide effective immunity against any microbe that comprises oligosaccharides having β-(1→6)-glucosamine structures in its cell walls.

Thus, unlike classic vaccines that vaccinate against a single bacteria, the vaccines described herein are capable of providing effective immunity against any microbe possessing the oligosaccharide structure described herein. Such microbes include, without limitation, Gram-positive bacteria, Gram-negative bacteria, antibiotic resistant bacteria (e.g., methicillin resistant *Staphylococcus aureus*), fungi, and the like provided that such microbes possess such oligosaccharide comprising β-(1→6)-glucosamine structures.

[0040] The term "effective immunity" as used herein refers to the ability of an effective amount of the vaccine to generate an antibody response *in vivo* that is sufficient to treat, prevent, or ameliorate a microbial infection wherein said microbe contains oligosaccharides comprising β-(1→6)-glucosamine in its cell walls. Assays to assess antibody response are conventional in art and include assays that evaluate the titer of antibody in response to microbes.

[0041] The vaccines and intermediates ("compounds") of this invention may exist as solvates, especially hydrates. Hydrates may form during manufacture of the compounds or compositions comprising the compounds, or hydrates may form over time due to the hygroscopic nature of the compounds. Compounds of this invention may exist as organic solvates as well, including DMF, ether, and alcohol solvates among others. The identification and preparation of any particular solvate is within the skill of the ordinary artisan of synthetic organic or medicinal chemistry.

[0042] "Subject" refers to a mammal. The mammal can be a human or non-human animal mammalian organism.

[0043] "Treating" or "treatment" of a disease or disorder in a subject refers to 1) preventing the disease or disorder from occurring in a subject that is predisposed or does not yet display symptoms of the disease or disorder; 2) inhibiting the disease or disorder or arresting its development; or 3) ameliorating or causing regression of the disease or disorder.

[0044] "Effective amount" refers to the amount of a vaccine of this invention that is sufficient to treat the disease or disorder afflicting a subject or to prevent such a disease or disorder from arising in said subject or patient.

[0045] The term "continuous immune protection" means that the patient has a therapeutic titer of antibody in the serum whether that titer comprises only F-598 antibody, polyclonal antibodies generated by the vaccine or a combination of both.

General Synthetic Methods

[0046] The compounds of this invention can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.

[0047] Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and P. G. M. Wuts, *Protecting Groups in Organic Synthesis*, Third Edition, Wiley, New York, 1999, and references cited therein.


[0048] The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the starting materials are available from commercial suppliers such as SigmaAldrich (St. Louis, Missouri, USA), Bachem (Torrance, California, USA), Emka-Chemce (St. Louis, Missouri, USA). Others may be prepared by procedures, or obvious modifications thereof, described in standard reference texts such as *Fieser and Fieser's Reagents for Organic Synthesis*, Volumes 1-15 (John Wiley, and Sons, 1991), *Rodd's Chemistry of Carbon Compounds*, Volumes 1-5, and *Supplementals* (Elsevier Science Publishers, 1989), *Organic Reactions*, Volumes 1-40 (John Wiley, and Sons, 1991), *March's Advanced Organic Chemistry*, (John Wiley, and Sons, 5th Edition, 2001), and *Larock's Comprehensive Organic Transformations* (VCH Publishers Inc., 1989).

Synthesis of Representative Compounds of the Invention

[0049] The general synthesis of the vaccines of this invention are known in the art and are disclosed in US Patent Application Serial No. 10/713,790 as well as in US Patent Nos. 7,786,255 and 8,492,364 each of which are incorporated herein by reference in its entirety.

Prior to conjugating the oligosaccharides to the toxoid, the toxoid itself may be purified so that it contains low levels of contaminant through phased filtrations, as disclosed in co-pending U.S. Patent Application No. 62/934,925, entitled "Low Contaminant Antimicrobial Vaccines," which is incorporated herein by reference in its entirety. By way of summary, the toxoid is purified through phased filtrations first to remove toxoids of oligomers higher than dimeric toxoid. The monomer and dimer pass through the filtrate. Lower molecular weight impurities are then separated on a smaller filter that isolates monomer and dimer toxoid, allowing small molecular weight impurities to pass through with the filtrate. In this way, good yields of conjugated vaccine with primarily monomer and dimer toxoid are prepared in good yields.


[0050] In the case of the specific vaccines described herein, the β-(1→6)-glucosamine group is limited to from 4 to 6 units and preferably 5 units. The formation of the linker group is achieved by art recognized synthetic techniques exemplified but not limited to those found in US Patent No. 8,492,364 and the examples below. In one embodiment, a first portion of the aglycon is attached to the reducing β-(1→6)-glucosamine unit retains a thiol (-SH) group as depicted below in formula III:



III

where *y* is an integer from 2 to 4.


[0051] The second portion of the linker is attached to the tetanus toxoid in the following manner as depicted in formula IV.



IV

[0052] In this formula, separate parts of tetanus toxoid are depicted by squiggly lines and are only illustrative in nature and are not intended to provide a complete structure of the toxoid. Any disulfide bridge is represented by a single line connecting the parts. For the sake of clarity, only a single second portion of the linker is illustrated whereas there are multiple such second portions covalently attached to amino groups found on the toxoid.

[0053] When the first and second portions of the linker are combined under coupling conditions, a thioether linkage is formed. The reaction is conducted in an inert diluent optionally in the presence of a base so as to scavenge the acid generated. The thioether linkage connects the first and second portions of the linker thereby providing for covalent linkage of the tetanus toxoid to the oligosaccharide β-(1→6)-glucosamine group through the combined linker as illustrated below for a vaccine structure where y is as defined herein.



[0054] It being understood that the number of β-(1→6)-glucosamine group – linker – moieties attached to the tentatus toxoid are stoichiometrically controlled so that the desired amount of such moieties are bound to the toxoid thereby providing for the vaccines of this invention.

Methods, Utility and Pharmaceutical Compositions

[0055] The vaccines used in the combinations of this invention are capable of initiating an effective immune response against microbes that possess PNAG oligosaccharide β-(1→6)-glucosamine structures in their cell walls wherein up to about 20% of said oligosaccharides are N-deacetylated. After inoculation of a patient, an effective immune response develops about 4 weeks later. This results in a latency period during which the vaccine is ineffective either prophylactically or therapeutically. In cases where the vaccine is administered prophylactically and the latency period is acceptable, the vaccines of this invention are useful in preventing subsequent microbial infections wherein the offending microbes have cell walls comprising PNAG.

[0056] When so used, a vaccine of this invention is administered to patients at risk of a microbial infection arising from such microbes. Such patients include, by way of example only, those who are elderly, burn patients especially patients having 20% or more burn coverage over their body, those with upcoming elected surgeries, those traveling to destinations where there is an outbreak of microbial infections, and the like. The vaccine is typically administered to an immune competent patient intramuscularly with a suitable adjuvant to enhance the immune response. After the latency period has passed, the patient has acquired natural immunity against such microbes.

[0057] In another embodiment, the vaccines of this invention can be used therapeutically particularly when the microbial infection is localized and/or non-life threatening. In such a case, a vaccine of this invention is administered to patients suffering from a microbial infection arising from such microbes. The vaccine is typically administered to an immune competent patient intramuscularly with a suitable adjuvant to enhance the immune response. Upon administration, effective immunity is generated within about 4 weeks. If the patient is still suffering from the infection, the natural immunity arising from the vaccine facilitates recovery.

[0058] As is apparent, it would be beneficial if anti-microbial therapy could be coupled with the vaccine especially for antibiotic resistant infections. Such would allow for immediate therapeutic treatment of a patient's infection rather than after the latency period. It is known that monoclonal antibodies generated against PNAG are useful therapeutically effective. One such example is a monoclonal antibody designated as F-598 and disclosed in US Patent No. 7,786,255 which is incorporated herein by reference in its entirety.

[0059] The use of such monoclonal antibodies with the vaccine described herein raises a problem in that the monoclonal antibody is designed to bind to PNAG. As such, administration of the monoclonal antibody with the vaccine would lead to binding of the antibody to the polyglucosamine portion of the vaccine rendering both ineffective.

[0060] Surprisingly, the vaccine described herein does not cross-react with the F-598 monoclonal antibody while inducing an endogenous immune response in the patient. Such a combination allows for co-administration of the vaccine with the F-598 antibody thereby allowing for immediate therapy based on the antibody alone during the latency period followed by an endogenous antibody production after the latency period. Such allows for treatment of patients with the F-598 monoclonal antibody during the latent period between administration of the vaccine and development of effective immunity. In this embodiment, therapeutic treatment of a patient suffering from an infection that is mediated by a microbe expressing PNAG on its cell wall can be initiated immediately with the antibody while also being concurrently administering the vaccine to the patient so as to develop natural immunity to the microbe. For the sake of completion, natural immunity refers to the immune response to an antigen whereby antibodies are generated that either alone or in combination with other components of the immune system kill the offending microbes.

[0061] When so used, the vaccines of this invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. The actual amount of the vaccine of this invention, i.e., the active ingredient, will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the vaccine

used, the route and form of administration, and other factors well-known to the skilled artisan.

[0062] An effective amount or a therapeutically effective amount of a vaccine of this invention, refers to that amount of vaccine that results in a sufficient titer of antibodies so as to ameliorate symptoms or a prolongation of survival in a subject. Toxicity and therapeutic efficacy of such vaccines can be determined by standard pharmaceutical procedures in cell cultures or experimental animals.

[0063] The vaccines described herein are typically administered as an injectable sterile aqueous composition that comprise one or more conventional components well known in the art including, by way of example only, adjuvants, stabilizers, preservatives and the like.

[0064] Likewise, the F-598 monoclonal antibody is administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. The actual amount of the antibody will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the route and form of administration, and other factors well-known to the skilled artisan.

[0065] An effective amount or a therapeutically effective amount of a vaccine of this invention, refers to that amount of antibody that results in a sufficient titer of antibodies so as to ameliorate symptoms or a prolongation of survival in a subject. The antibodies are preferably administered intravenously as an injectable sterile aqueous composition that comprise one or more conventional components well known in the art including, by way of example only, preservatives, and the like.

[0066] In some embodiments, the patient to be treated is a burn patient. Such patients are known to exude fluid from their burns and such fluid contains antibodies. Accordingly, overtime, the titer of antibodies, especially F-598, diminish leaving the patient with sub-optimal concentrations of the antibody. In such cases, it is preferred that the patient's antibody titer for F-598 be monitored and adjusted as necessary either by periodic administration or continuous administration of F-598.

[0067] In embodiments, there are provided methods of treating a patient at risk for developing a biofilm, the method comprising administering to the patient a combination of the vaccines disclosed herein along with the F-598 antibody. In embodiments, the methods may include identifying a patient at risk for developing a biofilm. Such patient populations include, without limitation, any patient undergoing some kind of surgical implant, such as a knee or hip replacement, a stent or catheter, and the like.

[0068] In embodiments, methods of treating a patient at risk for developing biofilm may include administering the F-598 antibody prior to any surgery. In some such embodiments, administration may take place at least 24 hours before surgery, or at least 72 hours before surgery, or at least 1 week before surgery, or at least two weeks before surgery. Where the patient is under duress for emergency surgery, the F-598 antibody can be administered just prior to or during surgery. In treating patients at risk of developing biofilms the PNAG vaccines can be administered at the same time as the F-598 antibody or sequentially. When administered sequentially, the PNAG vaccine is preferably administered within 24 hours of administration of the F-598 antibody.

COMBINATIONS

[0069] The combinations of this invention can be used in conjunction with other therapeutic compounds or other appropriate agents as deemed suitable by the attending clinician. In selected cases, the combinations of this invention can be concurrently administered with antibiotics for treating a bacterial infection, anti-fungals and the like. In the case of antibiotics, the selection of the appropriate antibiotic or cocktail of antibiotics and the amount to be administered to the patient is well within the skill of the attending physician based on the specifics of the offending bacteria, the extent of bacterial infection, the age, weight, and otherwise relative health of the patient. In the case of antifungal therapy, an effective amount of an antifungal medicament can be concurrently administered to the patient.

[0070] The vaccines of the invention may be administered with an antigen that potentiates the immune response to the antigen in the patient. Adjuvants include but are not limited to aluminum compounds such as gels, aluminum hydroxide and aluminum

phosphate, and Freund's complete or incomplete adjuvant (e.g., in which the antigen is incorporated in the aqueous phase of a stabilized water in paraffin oil emulsion. As is apparent, the paraffin oil can be replaced with other types of oils such as squalene or peanut oil. Other materials with adjuvant properties include BCG (attenuated Mycobacterium tuberculosis) calcium phosphate, levamisole, isoprinosine, polyanions (e.g., polyA:U), lentinan, pertusis toxin, lipid A, Saponins, QS-21 and peptides, e.g., muramyl dipeptide, and immuno stimulatory oligonucleotides such as CpG oligonucleotides. Rare earth salts, e.g., lanthanum and cerium, may also be used as adjuvants. The amount of adjuvant used depends on the subject being treated and the particular antigen used and can readily determined by one skilled in the art.

EXAMPLES

[0071] This invention is further understood by reference to the following examples, which are intended to be purely exemplary of this invention. This invention is not limited in scope by the exemplified embodiments, which are intended as illustrations of single aspects of this invention only. Any methods that are functionally equivalent are within the scope of this invention. Various modifications of this invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications fall within the scope of the appended claims.

[0072] The following terms are used herein and have the following meanings. If not defined, the abbreviation has its conventionally recognized definition.

Å	=	Angstroms
aq.	=	aqueous
Biotage	=	Biotage, Div. Dyax Corp., Charlottesville, Virginia, USA
bp	=	boiling point
CAD	=	charged aerosol detector
DCM	=	dichloromethane
deg	=	degree
DMSO	=	dimethylsulfoxide

eq.	=	equivalents
EtOAc	=	ethyl acetate
FEP	=	fluorinated ethylene propylene
g	=	gram
H^1-NMR	=	proton nuclear magnetic resonance
h	=	hour
HDPE	=	high density polyethylene
HPLC	=	high performance liquid chromatography
MeCN	=	acetonitrile
kg	=	kilogram
mbar	=	millibar
MeOH	=	methanol
mg	=	milligram
mL	=	milliliter
mM	=	millimolar
mmol	=	millimole
N	=	Normal
NBS	=	N-bromosuccinimide
NIS	=	N-iodosuccinimide
NMT	=	N-methyltryptamine
PP	=	polypropylene
qHNMR	=	quantitative proton nuclear magnetic resonance
RBF	=	round bottom flask
RO	=	reverse osmosis
SEC HPLC	=	size exclusion chromatography HPLC
SIM	=	secondary ion mass
TCEP	=	(tris(2-carboxyethyl)phosphine

TLC	=	thin layer chromatography
TMSOTf	=	methanesulfonic acid, 1,1,1-trifluoro-,trimethylsilyl ester
TT	=	tetanus toxoid
μL	=	microliter
μm	=	microns
w/w	=	weight to weight
w/v	=	weight to volume


Example 1 - Tentanus Toxoid Phased Fitration

[0073] Samples of crude tetanus toxoid preparations comprising monomeric and dimeric toxoid are first passed through a 3 to 5 micron filter to remove higher oligomers. This may be performed in phases of decreasing filter pore size. Thus, the toxoid preparation can be passed through a 5 micron filter, then a 3 micron filter. Alternatively, the toxoid preparation may be passed through a 5 micron filter, then 4 micron filter, then a 3 micron filter. The efficacy of a 5 micron filtration is assessed by light scattering techniques which can be used to detect the presence of higher oligomers. As needed, a stepped filtration is added to remove further higher oligomers. The resulting filtrate contains the monomer and dimeric toxoid. Where the chemistry for attachment of oligosaccharide follows complete purification, the filtrate is then passed through a 2.5 micron filter to allow isolation of the monomer and dimer toxoid as a filter cake, while low molecular weight impurities pass through with the filtrate. At each filtration step (high and low molecular weight), a rinse of the filter cake can be performed.

[0074] In one embodiment, the toxoid can be prepared to contain primarily monomers and dimers and less than 3% of small molecular weight impurities prior to attachment of the oligosaccharide β-(1→6)-glucosamine structures to the toxoid. See US Provisional Serial No. 62/934,925 which is incorporated herein by reference in its entirety.

Example 2 - Attachment of SBAP to TT Monomer


Step 1: Preparation of N-BABA:



1 2

[1] Commercially available beta-alanine, compound 1, is converted to N-BABA (bromoacetyl-β-alanine), compound 2, by reaction with at least a stoichiometric amount of commercially available bromoacetyl bromide. In a first container, β-alanine is combined into water with sodium bicarbonate or other suitable base to scavenge the acid that will be generated during the reaction. The aqueous solution is mixed at about 20 ± 5°C until a solution is obtained. The solution is then maintained at about 5 ± 5°C. In a separate container, the requisite amount of bromoacetyl bromide is added followed by the addition of dichloromethane. The contents of the both containers are combined. After reaction completion, 6N HCl is added and mixed to a pH approximately 2. The resulting N-BABA is extracted from the solution by a suitable solvent such as ethyl acetate. The organic layer is concentrated under conventional conditions such as under vacuum at an elevated temperature such as 60°C. Heptane is then added to precipitate N-BABA that is then collected on a filter and dried in a vacuum oven at 40°C. This product is used as is in the next step.

Step 2: Preparation of SBAP:




2 3

[0075] N-BABA, compound 2, is reacted with N-hydroxysuccinimide (NHS) under conventional conditions well known in the art to generate SBAP, compound 3. Specially, N-BABA is combined with at least a stoichiometric amount of NHS in a suitable inert solvent such as methanol, ethanol, isopropanol and the like. The resulting solution is stirred at about 20 ± 5°C until a clear solution is obtained. N-Diisopropylcarbodiimide is then added to the reaction mixture and mix with the generation of solids. The system is then cooled to 0 ± 5°C and resulting SBAP is provided by filtration. Further purification entails prechilling a mixture of isopropanol and heptanes and washing the filter cakes

followed by drying wet cake in a vacuum oven at about 30°C. The resulting SBAP is used as is in the coupling reaction with the TT monomer.

[0076] Alternatively, SBAP can be prepared in the manner set forth in US Patent No. 5,286,846, which patent is incorporated herein by reference in its entirety. Specifically, the method described therein is provided by the following synthetic scheme:




Step 3: Conjugation

[0077] Purified TT monomer, as described above, contains 43 lysine residues / mole as quantified by a free amine assay. Reaction of TT monomer with increasing concentrations of SBAP from 0 to 170 molar equivalents led to a corresponding decrease in the free amine content over the range 15-110 molar equivalents of SBAP. A steady state conversion was achieved at SBAP charges >110 equivalents. Assuming that the loss of free amines is directly proportional to loading of SBAP linker, the linker density at saturation was estimated to be 43 moles SBAP / TT monomer. The monomer/aggregate content of the linker TT/monomer intermediate and protein concentration at each titration point was also assessed. The monomer content prior to linker addition was 99.7 percent and addition of increasing amounts of SBAP linker did not significantly change the monomer level (no aggregate detected). Also, the recover of protein across the titration steps was similar. Based on this collective data, a value of 110 molar equivalents of SBAP for 1 hour at ambient temperature was selected as appropriate reaction conditions for all subsequent syntheses.

Example 3 - Oligosaccharide Synthesis

Synthesis of Building Blocks

[0078] The reaction scheme below illustrates for the synthetic steps used to prepare compounds 3, 5 and 8 that are elaborated upon below.



Synthesis of Compound D.

[0079] Commercially available 1,3,4,6-Tetra-O-acetyl-2-deoxy-2-N-phthalimido-β-D-glucopyranoside, compound C, (120.6 g, 252.6 mmol) and toluene (200 mL) were charged to a 1L Büchi flask and rotated at 40°C until dissolved (<5 minutes). The solvents were evaporated and to provide for a foam. Toluene (200 mL) was charged to the flask and rotated at 40°C until dissolved (<5 minutes). The solvents were evaporated again until dry. A crystalline solid formed, sticking to the walls. Dichloromethane (800 mL) was charged to the flask and rotated at ambient until dissolved; the resulting dark brown solution was charged to a 5L jacketed reactor and the flask was rinsed into the reaction with additional dichloromethane (200 mL). The heating/cooling jacket was set to 20°C and the reactor contents were stirred mechanically. Ethanethiol (40 mL, 540 mmol) was dissolved in 50 mL dichloromethane and added to vessel and the flask rinsed with 50 ml dichloromethane into the vessel. Boron trifluoride diethyl etherate (50 mL, 390.1 mmol) was dissolved in dichloromethane (50 mL) and added to the reactor, rinsed with dichloromethane (50 mL) and added to vessel. The mixture was stirred at 20°C for 2h. The reaction was checked by TLC for residual C. Mobile phase was toluene: ethyl acetate (3:1, v/v), Product Rf ~ 0.45, C Rf ~ 0.3 with UV visualisation. If significant amounts of C were present extended reaction time was required.

[0080] Stirring was set to a high speed and 4M aq. sodium acetate (1.25 L, 5100 mmol) was added. The phases were mixed well for 30 minutes. The pH of the aqueous

layer was checked with a dipstick and confirmed to be ~pH=7. Stirring was turned off and the reaction mixture was left standing for 70 minutes.

[0081] The layers were separated and collected. The organic layer (bottom layer, 1.2 L) and ethanol (840 mL, 14400 mmol) were charged to the reactor. The jacket was set to 60°C and solvent distilled under atmospheric pressure (dichloromethane bp 40 °C and ethanethiol bp 35°C, receiver flask in ice-bath). When the distillation slowed the jacket temperature was increased to 70°C. After 1300 mL of distillate were collected, a sample of the vessel content was taken and the ratio of dichloromethane to ethanol determined by ^{1}H-NMR and confirmed to be under 10 mol% dichloromethane. If more dichloromethane was present further distillation would be necessary. Additional ethanol was added (400 mL) followed by seed crystals of D. The jacket was cooled to 5°C over 30 minutes. The crystal slurry was stirred for 3 days at 5 °C. The solids were collected on a sintered funnel and washed with petroleum ether (60-80°C): 1x 500 mL slurry, 1x 300 mL plug. The solids were transferred to a 500 mL RBF and dried to constant weight (over ~4h) on a rotary evaporator (bath temperature 45°C) providing an off-white solid. Expected Yield: ~86 g (71% from C).

Synthesis of Compound 1

[0082] Anhydrous methanol (33 mL) was charged to a 50 mL round bottom flask. Sodium methoxide in methanol (30% solution, 25 µL, 0.135 mmol) was added and the resulting solution was stirred at ambient temperature for 5 minutes. Ethyl 3,4,6-tetra-O-acetyl-2-deoxy-2- N-phthalimido-β- thio-D-glucopyranoside (compound D) (3.09 g, 6.44 mmol) was added in portions (~200 mg) over 10 minutes, at a rate that allowed the solids to dissolve during addition. The reaction was stirred at ambient temperature for 2.5 h. TLC (EtOAc) showed complete consumption of compound D (Rf = 0.9) and formation of one, more polar spot: Rf = 0.5. A sample was taken and submitted for reaction completion IPC by HPLC (2.5µL reaction mixture in 0.8 mL acetonitrile and 0.2 mL water), pass condition was NMT 1.00 area% Compound D. Acetic acid was added (8 µL, 0.1397 mmol). The pH was checked with a dipstick and confirmed to be ~pH 5-6. The mixture was concentrated on a rotary evaporator (50°C) to near dryness. EtOAc (15 mL) was added and the majority evaporated. The residue was dissolved/slurried in 15 mL EtOAc and removed from the rotary evaporator. 2 mL petroleum ether was added and the mixture

was stirred at ambient temperature. The crystal slurry was stirred overnight. The solids were collected on a sintered funnel, washed with petrol (2 x 10 mL) and dried on rotary evaporator (45°C bath temperature) to constant weight. Expected Yield: 1.94 g (85% from Compound D).

Synthesis of Compound 2

[0083] Compound 1 (2.040 g) was dissolved in pyridine (28 mL) and the solution concentrated to approximately half the volume (~14 mL) in a rotary evaporator at 40°C bath temperature to give a yellow solution. More pyridine was added (14 mL) and again the solution concentrated to approximately 14 mL in the same manner. The solution was placed under argon and trityl chloride (2.299 g, 1.36 eq) was added before an air-cooled condenser was attached and the solution heated to 50 °C with stirring. After 4 hours an IPC was run (HPLC; 5 µL into 800 µL MeCN, residual compound 1 NMT 3.00 area%). As soon as the IPC was met the reaction was cooled to 10-15 °C. Benzoyl chloride (1.60 mL, 2.34 eq) was added dropwise over a period of 20 minutes keeping the reaction temperature below 20 °C. Once addition was complete, the reaction was allowed to warm to ambient temperature and stirred for at least 3 h. At this time an IPC was run (HPLC; 5 µL into 1500 µL MeCN, residual mono-Bz derivatives of compound 1 NMT 3.00 area% total). As soon as the IPC was met the reaction was cooled to 0 °C and quenched by the slow addition of methanol (0.8 mL), ensuring the reaction temperature remains below 20 °C. The quenched reaction was then warmed to ambient temperature.

[0084] The product mixture was diluted with toluene (20 mL) and stirred for 1 hour at ambient temperature before the precipitate was removed by filtering through a sintered funnel. The toluene solution was then washed with citric acid (20% w/w, 4 x 20 mL) followed by saturated NaHCO3 (9 % w/v, 20 mL) which resulted in a minor reaction with any residual citric acid present. The toluene (upper) layer was then washed with brine (20 mL) before being evaporated in a rotary evaporator at 40°C bath temperature to give a yellow/orange syrup (6.833 g). The syrup was submitted for IPC (H^1 NMR, pass condition NMT 30 wt% residual toluene). Expected Yield: ~6.833 g (147 %).

Synthesis of Compound 3

[0085] Glacial acetic acid (648 mL) and ultrapure water (72 mL) were mixed together to give a 90 % acetic acid solution. A portion of the acetic acid solution (710 mL) was added to crude compound 2 (111 g) along with a stirrer bar. An air cooled condenser was attached to the flask and the mixture was then heated to 70°C. Due to the viscous nature of 2, the mixture was not fully dissolved until 1 hour and 20 minutes later, at which point stirring began. After 2 hours an IPC was run (HPLC; 5 µL into 800 µL MeCN, residual compound 2 NMT 3.00 area %). As soon as the IPC met the specs, the reaction was cooled to ambient temperature. The mixture was transferred to a sintered funnel and the precipitated trityl alcohol (31.09 g) filtered off using house vacuum. The flask was rinsed with a further portion of 90% acetic acid (40 mL) and the total washings transferred to a mixing vessel. Toluene (700 mL) and water (700 mL) were added and mixed thoroughly. The aqueous (lower) layer was a cloudy white solution and was tested for pH (it was expected to be < 2). The wash was repeated twice more with water (2 x 700 mL; pH of ~2.4 and ~3 respectively, colorless clear solutions). Saturated $NaHCO_3$ (9 % w/v, 700 mL) was added to the mixing vessel resulting in a minor reaction (gas evolution). The toluene (upper) layer was then washed with brine (700 mL) before being evaporated in a rotary evaporator at 40°C bath temperature to give a yellow/orange solid/liquid mixture (86 g). This mixture was dissolved in 400 mL toluene (300 mL + 100 mL washings) and loaded on to a silica column (450 g silica) which was equilibrated with 3 column volumes (CV) of petroleum ether:toluene (1:1, v:v). The column was eluted using a stepwise gradient, fractions of 1 CV (790 mL) were collected. The gradient used was:

4 vol% ethyl acetate in petroleum ether:toluene (1:1 v:v, 4 CVs) L SEP

8 vol% ethyl acetate in petroleum ether:toluene (1:1 v:v, 12 CVs) L SEP

15 vol% ethyl acetate in petroleum ether:toluene (1:1 v:v, 4 CVs) L SEP

20 vol% ethyl acetate in petroleum ether:toluene (1:1 v:v, (4 CVs) L SEP

30 vol% ethyl acetate in petroleum ether:toluene (1:1 v:v, 1 CV) L SEP

[0086] The product eluted over 14 fractions. TLC was used to locate the product containing fractions. All fractions were submitted to IPC (HPLC, NMT 1.50 area% of the peak at 10.14 minutes and NMT 1.50 area% of the peak at 10.94 mins). Fractions not meeting IPC were set aside for processing to compound 4. The combined fractions were

evaporated in a rotary evaporator at 45°C bath temperature to give a colorless syrup. Expected Yield: ~60 g, (78 %).

Synthesis of Compound 4

[0087] Crude compound 3 (39.54 g, containing ~ 21 g of compound 3, ~37 mmol, taken just prior to chromatography of 3) was dissolved in toluene (7.2 mL) and dry pyridine (14.2 mL, 176 mmol, ~4.8 eq.) added to give a homogenous solution. Acetic anhydride 7.2 mL (76 mmol, ~2.1 eq.) was added and the mixture stirred for 18 h at 25°C. During the reaction solids precipitate, some of this precipitate was likely to be compound 4. The reaction was sampled for IPC, if the amount of compound 3 detected was > 1.00 area % then further charges of dry pyridine (1.4 mL, 17 equivs) were added and the reaction continued until residual compound 3 was ≤ 1.00 area % in the liquid phase.

[0088] The reaction was diluted with dichloromethane (112 mL) then water (2.8 mL) and methanol (2.8 ml) were added. The mixture was stirred for 3 h at 25 °C. This stir period was shown sufficient to quench the excess acetic anhydride. The mixture was washed with citric acid monohydrate/water 20/80 w/w (112 mL). The aqueous phase was back-extracted with dichloromethane (50 mL). The dichloromethane that was used for the back-extract was set aside and used to back-extract the aqueous phases from the remaining citric acid washes. The main dichloromethane extract was returned to the vessel and the citric acid washing process repeated until the pH of the aqueous phase was ≤ 2 (typically two further washes). The combined citric acid washes were back-extracted. The back-extract and main dichloromethane extract were then combined. The resulting dichloromethane solution was washed with 5% w/v NaHCO3 (100 mL), the dichloromethane phase was taken and washed with water (100 mL). The dichloromethane phase was transferred to an evaporating vessel and ethyl acetate (50 mL) was added and the solution concentrated to a syrup.

[0089] Ethyl acetate (150 mL) was added and the product dissolved by heating to 55°C with stirring. Petroleum ether 60-80 (200 mL) was added and the solution re-heated to 55°C and held for 5 min. The solution was cooled to 45°C and seed crystals (30 mg) added, it was then cooled to 18°C over 3 h with stirring and held at 18°C for at least 1 h. The crystals were collected by filtration and washed with ethyl acetate/petroleum ether

(1/2 v/v, 60 mL). Drying *in vacuo* afforded compound 4 (16.04 g, 77% from 2). Expected Yield: 16.0 g (77 % from Compound 2).

Synthesis of Compound 3.1

[0090] 3-aminopropan-1-ol (7.01 g, 93 mmol) was dissolved in DCM (70 mL) and cooled to 0°C. Benzyl chloroformate (5.40 mL, 32 mmol) was dissolved in DCM (20 mL) and added dropwise keeping the internal reaction temp below 10°C. Once complete, the flask was stirred at room temperature for 2 h. A sample removed for NMR analysis (IPC: 20 ?L + 0.6 mL d6-DMSO) indicated that the benzyl chloroformate reagent had been consumed. The product mixture was then washed with citric acid (10% w/w, 2 x 90 mL), water (90 mL) and brine (90 mL). The DCM (lower) layer was then evaporated in a rotary evaporator at 40 °C bath temperature to give a slightly cloudy oil/liquid (6.455 g). This oil was dissolved in ethyl acetate (7 mL), warming to 40 °C if necessary to dissolve any precipitated solid, and then allowed to cool to room temperature. Petroleum ether (4 mL) was added slowly to the stirring solution along with a seed crystal, at which point the product started crystallizing slowly. Once the majority of the product had precipitated, the final portion of petroleum ether (17 mL) was then added slowly (total solvent added: ethyl acetate:petroleum ether 1:3, 21 mL). The product was then filtered under vacuum and washed with petroleum ether (5 mL) to give the product as a fine white powder (4.72 g). Expected Yield: ~4.7 g (61 %).

Synthesis of Compound 5

[0091] Compound 4 (1.05 g, 1.73 mmol) was dissolved in dry acetone (12 mL, 0.06 % w/w water) and water (39 µL, 2.15 mmol, 1.3 eq.) at ambient temperature. The solution was then cooled to -10°C. NBS (0.639 g, 3.59 mmol, 2.08 eq.) was added in one portion. An exotherm in the order of +7°C was expected and the solution was then immediately re-cooled to -10°C. 15 minutes after the NBS addition, the reaction mixture was submitted for IPC (HPLC, pass condition less than 2.00 area % compound 4 remaining). If the reaction was not complete, 1.00 eq. of NBS (0.307 g, 1.73 mmol, 1.00 eq.) was added in one portion, the reaction was then held at -10°C for another 15 minutes and a further IPC carried out. The reaction was quenched by adding aqueous $NaHCO_3$ (5% w/v, 5 mL) and cooling was stopped and the mixture allowed to warm to 10-20°C during the following additions. After 3-5 minutes of stirring, further aqueous $NaHCO_3$ (5% w/v,

5 mL) was added and stirring continued for 5 minutes. A final aliquot of aqueous $NaHCO_3$ (5% w/v, 10 mL) was added with stirring followed by sodium thiosulfate (20% w/v, 5 mL). The mixture was stirred for 20 min. at 10-20°C and the solids were then collected by filtration. The vessel was rinsed onto the filter pad with $NaHCO_3$ (5% w/v, 25 mL) and this rinse was filtered off. The filter cake was then rinsed successively with $NaHCO_3$ (5% w/v, 25 mL) and then water (25 mL). The (still-damp) filter cake was dissolved in DCM (20 mL) and washed with two lots of $NaHCO_3$ (5% w/v, 20 mL) and then once with water (20 mL). The dichloromethane layer was dried by rotary evaporation and then dissolved in ethyl acetate (36 mL) at 65°C. Petroleum ether 60-80 (10 mL) was then added slowly with stirring and the mixture cooled to 45°C and stirred at 45°C for 30 min. Additional petroleum ether 60- 80 (22 mL) was added with stirring and the stirred mixture cooled to 15°C over 2h. The product was collected by filtration, washed with petroleum ether/ethyl acetate 2/1 v/v (20 mL) and then dried under vacuum to give compound 5 (0.805 g, 83% yield, α and β anomers combined purity by HPLC was 98%).

Synthesis of Compound 7

[0092] Compound 4 (500 mg) and intermediate 3.1 (211 mg, 1.2 eq.) were weighed into a dry flask, toluene (5 mL) was added and the solution concentrated on a rotary evaporator (45°C bath temperature). This was repeated once more before the starting materials were concentrated from anhydrous DCM (5 mL). Once all of the solvent was removed, the residual solid was dried under vacuum for 10 minutes. Following drying, the starting materials were placed under argon, dissolved in anhydrous DCM (5.0 mL) and activated 4Å molecular sieves (450 mg, pellet form) were added. At this point, the NIS reagent was placed under high-vacuum to dry. After 10 minutes, the dried NIS (400 mg, 2.0 equivalents) was added and the solution stirred at room temperature for 30 minutes. TMSOTf (8 µL, 5 mol%) was then added quickly, which results in the solution changing from red/orange to a deep red/brown color. The reaction temperature also rose from 22 to 27 °C. As soon as the TMSOTf was added an IPC was run for information only (HPLC; 10 µL into 1 mL MeCN-H_2O (8:2)). The reaction was then quenched by the addition of pyridine (20 µL, 0.245 mmol) and stirred at ambient temperature for 5 minutes. The DCM solution was filtered to remove the molecular sieves and then washed with 10% Na2S2O3 (3 x 5 mL), brine (5 mL) and then concentrated on a rotary evaporator (40°C

bath temperature) to give crude compound 7 as a foamy yellow oil (616 mg). Expected Yield: ~616 mg, (99 %).

Synthesis of Compound 8

[0093] Crude compound 7 (16.6 g) was dried by evaporation from toluene (2 x 30 mL) then from anhydrous DCM (30 mL) to produce a yellow foam/oil. The flask was then placed under an argon atmosphere before anhydrous DCM (100 mL) and dry MeOH (260 mL) was added and the mixture stirred. The flask was then cooled to 0°C. Acetyl chloride (3.30 mL, 2.0 eq.) was added dropwise while maintaining an internal temp of less than 10°C. Once addition was complete, the mixture was stirred at ambient temperature for 16 hours. At this point an IPC was run (HPLC; 20 µL into 1 mL MeCN, residual compound 7 no more than 3 area %). The flask was then cooled to 0°C and the pH of the product solution adjusted to pH 6.5-7.5 by the addition of N-methylmorpholine (7.0 mL total required). The product mixture was diluted with DCM (50 mL) and washed with H_2O (2 x 200 mL). The second H_2O wash was cloudy and contained target material by TLC so this was back-extracted with DCM (50 mL). The combined DCM layers were then washed with brine (8 mL) before being evaporated in a rotary evaporator at 40°C bath temperature to give an off-white foam/oil (~16.8 g). This mixture was dissolved in 140 mL toluene (100 mL + 40 mL washings) and loaded onto a silica column (85 g silica) which was equilibrated with 3 column volumes (CV) of 30 vol% ethyl acetate in petroleum ether. The column was eluted using a stepwise gradient, fractions of 1 CV (140 mL) were collected. The gradient used was:

30 vol% ethyl acetate in petroleum ether (3 CVs) L SEP

35 vol% ethyl acetate in petroleum ether (4 CVs) L SEP

40 vol% ethyl acetate in petroleum ether (9 CVs) L SEP


50 vol% ethyl acetate in petroleum ether (4 CVs) L SEP

60 vol% ethyl acetate in petroleum ether (3 CVs) L SEP

The product eluted over 12 fractions. All fractions were submitted to IPC (HPLC, NMT 1.50 area% of any impurity peak at 230 nm). The combined fractions were evaporated in a rotary evaporator at 40°C bath temperature to give an off-white foam which solidified to afford 8 as a crunchy solid (10.45 g). Expected Yield: 10.45


g (66 %).

Example 4 - Synthesis of Disulfide (Compound 17)



Compound 17

[0094] The overall synthetic procedure for the synthesis of compound 17 is described in the synthetic scheme below.



Synthesis of Compound 9

[0095] Compound 5 (1620 g, 1.18 eq.) and toluene (18 kg) were charged to a 50 L Büchi bowl in that order. The bowl was warmed in a water bath with a setting of 50 ± 10°C for 30 min. Evaporation was run under vacuum using a water bath temperature of 50 ± 10°C until no more solvent distilled. The water bath was cooled to 20 ± 10°C. Trichloroacetonitrile (7.1 kg, 21 equiv.) and dry DCM (6.5 kg) were charged to the bowl under nitrogen atmosphere. A suspension of sodium hydride (5.6 g, 0.060 equiv.) in dry DCM (250 g) was charged to the bowl under nitrogen atmosphere. The bowl contents were mixed by rotation for 1 - 2 h with a water bath temperature of 20 ± 10°C. Compound 5 dissolved during the reaction. The bowl contents were sampled and submitted for reaction completion IPC (H^1 NMR, integrating triplet peak at 6.42 ppm (product) relative to triplet at 6.35 ppm (starting material); pass condition ≤ 5 % residual starting material). Compound 3 (1360 g, 2.35 mol), dry DCM (12.3 kg) and powdered molecular sieves 4Å (136 g) were charged to the 50 L reactor in that order. The reactor contents were mixed for 24 h. The reactor contents were sampled through a syringe filter and analyzed by Karl Fisher (AM-GEN-011, pass condition ≤ 0.03 %w/w). After reaching the moisture threshold (~24 h), the reactor contents were adjusted to 0 ± 5°C. The contents of the Büchi bowl were transferred to the reactor header as volume allowed. A solution of trimethylsilyl trifluoromethanesulfonate (100 g, 0.18 eq.) in dry DCM (1250 g) was charged to the reactor under a nitrogen atmosphere. The header contents were drained to the reactor maintaining the reactor contents at 0 ± 10°C throughout the addition. Addition took 15 - 20 min. Dry DCM (1250 g) was charged to the Büchi bowl and then transferred to the reactor header. The header contents were drained to the reactor maintaining the reactor contents at 0 ± 10°C throughout the addition. The reactor contents were stirred at 0 ± 5°C for 60 min. The reactor contents were sampled for reaction completion using IPC (HPLC, pass criteria ≤ 5 % starting material). The reaction was quenched by charging N-methylmorpholine (85 g, 0.36 eq.) to the reactor. The reactor contents were sampled for quench completion using IPC (wetted pH paper, pass criteria ≥ pH 7). Silica gel (4.9 kg) was charged to the Büchi bowl. The reactor contents were transferred to the Büchi bowl. Evaporation was run under vacuum using a water bath temperature of 40 ± 10°C until no more solvent distilled. Silica gel (1.4 kg) was charged to the Büchi bowl followed by dichloromethane (7.0 kg) used to rinse the reactor.

The bowl contents were rotated to ensure solids were not adhered to the bowl surface. Evaporation was run under vacuum using a water bath temperature of 40 ± 10°C until no more solvent distilled. The bowl contents were divided into three portions for silica gel chromatography. A 150 L KP-SIL cartridge was installed in the Biotage system. Ethyl acetate (7.8 kg) and petroleum ether (22 kg) were charged to the 50 L reactor along with 1/3 of the reaction mixture adsorbed onto silica gel, mixed thoroughly and then transferred to a Biotage solvent reservoir. The solvent reservoir contents were eluted through the column so as to condition the column. The eluent was collected in 20 L jerry cans and discarded. The column was run in three batches and each was eluted with ethyl acetate/petroleum ether as described below:

[0096] Ethyl acetate (1.6 kg) and Petroleum ether (4.4 kg) were charged to a Biotage solvent reservoir, mixed thoroughly and then eluted through the column. Column run-off was collected in 20 L jerry cans. [L SEP]

[0097] Ethyl acetate (25 kg) and Petroleum ether (26 kg) were charged to the 50 L reactor, mixed thoroughly, transferred to two Biotage solvent reservoirs and then eluted through the column. Column run-off was collected in 20 L jerry cans. [L SEP]

[0098] Ethyl acetate (31 kg) and Petroleum ether (22 kg) were charged to the 50 L reactor, mixed thoroughly, transferred to two Biotage solvent reservoirs and then eluted through the column. Column run-off was collected in 5 L glass lab bottles. [L SEP]

[0099] Ethyl acetate (16 kg) was charged to a Biotage solvent reservoir and then eluted through the column. Column run-off was collected in 20 L jerry cans. [L SEP]

[00100] The column was repeated as above with the remaining two portions of dry load silica prepared. [L SEP]

[00101] The column fractions were sampled for product purity (TLC [10 % acetone in toluene, Rf 0.5] to identify fractions with product. The accepted column fractions were combined and in a 100 L Büchi bowl. Toluene was used to rinse any crystalline material from accepted fraction vessels into the bowl. Evaporation was run under vacuum using a water bath temperature of 40 ± 10°C until no more solvent distilled. Toluene (1.7 kg) was charged to the bowl and to contents rotated until the solids dissolved. t-Butyl methyl

ether (4.4 kg) was charged to the bowl over 20-40 min. The bowl contents were rotated for 12-24 h at a temperature of 20 ± 5°C. The bowl contents were transferred to a 6 L Nutsche filter and the solvent removed by vacuum filtration. t-Butyl methyl ether (620 g) was charged to the bowl, transferred to the Nutsche filter and passed through the filter cake. The filter cake was air dried in the filter then transferred to a vacuum oven and dried at a setting of 30°C under vacuum to remove residual solvent. The solid was sampled for analytical and retention. The solid was transferred to screw-top Nalgene containers and stored at ≤-15 °C. Expected Yield: 1.68 – 1.94 kg compound 9 (65-75 %).

Synthesis of Compound 10

[00102] Reagents were prepared as follows: N-Iodosuccinimide (241 g, 2.20 eq.) was dried in a vacuum oven with a setting of 30°C under vacuum for 24 h. A solution of sodium chloride (300 g) in water (3000 g) was prepared in a 5 L lab bottle. A solution of sodium thiosulfate (1100 g) in water (6000 g) was prepared in a 50 L reactor and distributed into two portions.

[00103] Compound 8 (355 g, 0.486 mol) and Compound 9 (634 g, 1.10 eq.) were charged to a 20 L Büchi bowl followed by toluene (1500 g) and heated at 40 ± 5°C until dissolved. Evaporation was run under vacuum using a water bath temperature of 35 ± 10°C until no more solvent distilled. Toluene (1500 g) was charged to the Büchi bowl. Evaporation was run under vacuum using a water bath temperature of 35 ± 10°C until no more solvent distilled. Dry dichloromethane (4000 g) was charged to the Büchi bowl. The bowl was rotated until the solids dissolved and the solution was transferred to a 5L reactor with a jacket temperature of 20°C ± 5°C. Dry dichloromethane (710 g) was charged to the Büchi bowl. The bowl was rotated to rinse the bowl surface and the solution was transferred to the 5 L reactor. The reactor contents were sampled for reagent ratio IPC (H^1 NMR). Dried N- Iodosuccinimide was charged to the reactor under a nitrogen atmosphere and the reactor was stirred for 5-15 min. The reactor contents were adjusted to 20°C ± 3°C. Trimethylsilyl trifluoromethanesulfonate (5.94 g, 0.055 eq.) in dry DCM (60 g) was charged to the reactor over 5-15 min. maintaining the contents temperature at 20°C ± 3°C. The reaction mixture was stirred at 20°C ± 3°C for 20 ± 3 min. The reactor contents were sampled for reaction completion (HPLC). N-Methylmorpholine (98 g, 2 equiv.) was charged to the reactor and mixed thoroughly. One

of the portions of the sodium thiosulfate solution prepared above was charged to the 50 L reactor. The 5L reactor contents were transferred to the 50L reactor containing the sodium thiosulfate solution and mixed thoroughly. The bottom layer was discharged to a HDPE jerry can.

[00104] DCM (570 g) was charged to the 5 L reactor with the top layer from the 50L reactor and mixed thoroughly. The bottom layer was combined with the previous bottom layer in the HDPE jerry can. The top layer was transferred to a separate HDPE jerry can and retained until yield was confirmed. The combined organic phase (bottom layers) were charged to the 50 L reactor followed by another portion of sodium thiosulfate and mixed thoroughly. The bottom layer was discharged to a HDPE jerry can. The top layer was retained in a HDPE jerry can until yield was confirmed. The sodium chloride solution was charged to the 50L reactor along with the organic phase (bottom layers) and mixed thoroughly. Silica gel (1300g) was charged to a Büchi bowl and fitted with a rotary evaporator. The bottom layer in the reactor was charged to the Büchi bowl. The bowl contents were rotated to prevent adsorption onto the bowl and evaporated under vacuum using a water bath temperature of 40 ± 5°C until no more solids distilled. The bowl contents were divided into two equal portions. Silica gel (200g) was charged to the Büchi bowl followed by dichloromethane (700 g). The bowl contents were rotated to ensure solids did not adhere to the bowl surface. The bowl was evaporated under vacuum at a water bath temperature of 40°C ± 10°C until no more solvent distilled. The bowl contents were divided into two portions and a portion was added to each of the previous silica gel samples.

[00105] Each portion was purified independently on silica gel using the following procedure (samples were stored at ≤15°C while awaiting purification): A 150 L KP-SIL cartridge was installed in the Biotage system. Ethyl acetate (15.5 kg) and petroleum ether (16.5 kg) were charged to the 50 L reactor, mixed thoroughly and then transferred to two Biotage solvent reservoirs. The solvent reservoirs contents were eluted through the column so as to condition the column. The eluent was collected in 20 L jerry cans and discarded. A portion of the dry load silica from above was charged to the Biotage Sample-Injection Module (SIM) and then eluted with the ethyl acetate/petroleum ether as follows:

[00106] Ethyl acetate (6.2 kg) and Petroleum ether (6.6 kg) were charged to a 50L reactor, mixed thoroughly and then transferred to a Biotage solvent reservoir. Column run-off was collected in 20 L jerry cans.

[00107] Ethyl acetate (19.5 kg) and Petroleum ether (19.2 kg) were charged to the 50 L reactor, mixed thoroughly, transferred to two Biotage solvent reservoirs and then eluted through the column. Column run-off was collected in 20 L jerry cans.

[00108] Ethyl acetate (13.6 kg) and Petroleum ether (12.3 kg) were charged to the 50 L reactor, mixed thoroughly, transferred to two Biotage solvent reservoirs and then eluted through the column. Column run-off was collected in 20 L jerry cans.

[00109] Ethyl acetate (14.2 kg) and Petroleum ether (11.9 kg) were charged to the 50 L reactor, mixed thoroughly, transferred to two Biotage solvent reservoirs and then eluted through the column. Column run-off was collected in 20 L jerry cans.

[00110] Ethyl acetate (29.7 kg) and Petroleum ether (22.9 kg) was charged to a Biotage solvent reservoir and then eluted through the column. Column run-off was collected in 20 L jerry cans up to fraction 11 and then 5L HDPE jerry cans.

[00111] Ethyl acetate (15.5 kg) and Petroleum ether (11.0 kg) was charged to a Biotage solvent reservoir and then eluted through the column. Column run-off was collected in 5L HDPE jerry cans.

[00112] Ethyl acetate (29.7 kg) and Petroleum ether (13.2 kg) was charged to a Biotage solvent reservoir and then eluted through the column. Column run-off was collected in 5L HDPE jerry cans.

[00113] Ethyl acetate (15.5 kg) was charged to a Biotage solvent reservoir and then eluted through the column. Column run-off was collected in 5L HDPE jerry cans.

[00114] Column fractions were sampled for product purity (TLC to identify fractions with product). Fractions that were 75 – 95 % area compound 10 from the first two columns were combined in a Büchi bowl charged with silica gel (400 g) and evaporation was run under vacuum using a water bath temperature of 40 ± 10°C until no more solvent distilled. The contents of the bowl were purified as follows: A 150 L KP-SIL

cartridge was installed in the Biotage system. Ethyl acetate (15.5 kg) and petroleum ether (16.5 kg) were charged to the 50 L reactor, mixed thoroughly and then transferred to two Biotage solvent reservoirs. The solvent reservoirs contents were eluted through the column so as to condition the column. The eluent was collected in 20 L jerry cans and discarded. The bowl contents were charged to the Biotage Sample-Injection Module (SIM) and then eluted with the ethyl acetate/petroleum ether as follows:

[00115] Ethyl acetate (6.2 kg) and Petroleum ether (6.6 kg) were charged to a 50L reactor, mixed thoroughly and then transferred to a Biotage solvent reservoir. Column run-off was collected in 20 L jerry cans.

[00101] Ethyl acetate (19.5 kg) and Petroleum ether (19.2 kg) were charged to the 50 L reactor, mixed thoroughly, transferred to two Biotage solvent reservoirs and then eluted through the column. Column run-off was collected in 20 L jerry cans.

[00102] Ethyl acetate (13.6 kg) and Petroleum ether (12.3 kg) were charged to the 50 L reactor, mixed thoroughly, transferred to two Biotage solvent reservoirs and then eluted through the column. Column run-off was collected in 20 L jerry cans.

[00103] Ethyl acetate (14.2 kg) and Petroleum ether (11.9 kg) were charged to the 50 L reactor, mixed thoroughly, transferred to two Biotage solvent reservoirs and then eluted through the column. Column run-off was collected in 20 L jerry cans.

[00104] Ethyl acetate (29.7 kg) and Petroleum ether (22.9 kg) was charged to a Biotage solvent reservoir and then eluted through the column. Column run-off was collected in 20 L jerry cans up to fraction 11 and then 5L HDPE jerry cans.

[00105] Ethyl acetate (15.5 kg) and Petroleum ether (11.0 kg) was charged to a Biotage solvent reservoir and then eluted through the column. Column run-off was collected in 5L HDPE jerry cans.

[00106] Ethyl acetate (29.7 kg) and Petroleum ether (13.2 kg) was charged to a Biotage solvent reservoir and then eluted through the column. Column run-off was collected in 5L HDPE jerry cans.

[00107] Ethyl acetate (15.5 kg) was charged to a Biotage solvent reservoir and then eluted through the column. Column run-off was collected in 5L HDPE jerry cans.

[00108] The accepted column fractions from all three columns were combined in a Büchi bowl and evaporation was run under vacuum using a water bath with temperature of 40°C ± 10°C until no more solvent distilled. The contents of the bowl was sampled for analytical and retention. The bowl was sealed and transferred to storage at ≤ –15 °C. Expected Yield: 440 – 540 kg (52 – 64 % yield).

Synthesis of Compound 11

[00109] Dichloromethane was charged to a Büchi bowl containing compound 10 (635 g, 0.345 mol) (PN0699) and heated at 30 ± 10°C until dissolved. Methanol (3.2 kg) was charged to the bowl. The content of the bowl were adjusted to 0 ± 3°C. Acetyl chloride (54.1 g, 2 equiv.) in dichloromethane (660 g) was charged to the bowl maintaining the contents temperature at 0 ± 10°C. The bowl contents were adjusted to 20 ± 3°C and the mixture was stirred for 40-48 h. The bowl contents were sampled for reaction completion IPC (HPLC, pass). The bowl contents were adjusted to 0 ± 3°C. N-methylmorpholine (139 g, 4 equiv.) was charged to the bowl and mixed thoroughly. The bowl contents were sampled for quench completion IPC (pH paper, pass ≤ pH7). The bowl contents were concentrated under vacuum with water bath at 35 ± 10°C. Ethyl acetate (4.8 kg) and water (5.5 kg) were charged to the Büchi bowl and rotated to dissolve the bowl contents. The bowl contents were transferred to a 50L reactor and mixed thoroughly. The bottom layer was drained to a HDPE jerry can. The top layer was transferred to a Büchi bowl fitted with a rotary evaporator and the contents were concentrated under vacuum with a water bath at 35 ± 10°C. The bottom layer from the HDPE jerry can was charged to a 50L reactor with ethyl acetate (1.5 kg) and mixed thoroughly. The bottom layer was drained to a HDPE jerry can and held until yield was confirmed. The top layer was transferred to the Büchi bowl fitted with a rotary evaporator and the contents were concentrated under vacuum with a water bath at 35 ± 10°C. The contents of the bowl were sampled for analytical and retention. The bowl was sealed and transferred to storage at ≤ –15 °C. Expected Yield: 518 – 633 kg (90 – 110 % yield).

Synthesis of Compound 12

[00110] Reagents were prepared as follows: Two portions of N-Iodosuccinimide (143 g, 3.90 eq.) were dried in a vacuum oven with a setting of 30°C under vacuum for 24 h. A solution of sodium chloride (450 g) in water (1850 g) was prepared in a 5 L lab bottle and distributed to 2 approximately equal portions. A solution of sodium thiosulfate (230 g) in water (2080 g) was prepared in a 5 L lab bottle and distributed to 4 approximately equal portions.

[00111] Compound 9 (504 g, 1.30 eq.) was charged to a 50 L Büchi bowl containing compound 11 (607 g, 0.327 mol) followed by toluene (1500 g) and heated at 40 ± 5°C until dissolved. Evaporation was run under vacuum using a water bath temperature of 35 ± 10°C until no more solvent distilled. Toluene (1500 g) was charged to the Büchi bowl. Evaporation was run under vacuum using a water bath temperature of 35 ± 10°C until no more solvent distilled. Dry DCM (2400 g) was charged to the Büchi bowl. The bowl was rotated until the solids dissolved and half the solution transferred to the 5L reactor with a jacket temperature of 20°C ± 5°C. The second half of the solution was transferred to a 5 L lab bottle. Dry DCM (710 g) was charged to the Büchi bowl. The bowl was rotated to rinse the bowl surface and half the solution was transferred to the 5 L reactor. The other half was charged to the 5 L lab bottle above and stored under nitrogen for use in the second batch. A portion of dried N-Iodosuccinimide was charged to the reactor under a nitrogen atmosphere. The reactor contents were adjusted to –40°C ± 3°C. Trimethylsilyl trifluoromethanesulfonate (9.09 g, 0.25 effective equiv.) in dry dichloromethane (90 g) was charged to the reactor over 15 min. maintaining the contents temperature at –40°C ± 5°C. The reaction mixture was stirred at –40°C ± 3°C for 30 ± 5 min. then adjusted to –30°C ± 3°C over and stirred for 150 min. The reactor contents were sampled for reaction completion. N-Methylmorpholine (33.1 g, 2 effective eq.) was charged to the reactor and mixed thoroughly. One of the portions of the sodium thiosulfate solution prepared above was charged to the 5 L reactor and mixed thoroughly. The bottom layer was discharged to a 5 L lab bottle. DCM (400 g) was charged to the 5 L reactor and mixed thoroughly. The bottom layer was combined with the previous bottom layer in a 5L lab bottle. The combined organic phases were charged to the 5 L reactor followed by another portion of sodium thiosulfate and mixed thoroughly. The bottom layer was discharged to a 5 L lab bottle. A portion of sodium chloride solution from above was charged to the reactor followed by the content of the previous lab bottle. The bottom layer in the reactor was

charged to the Büchi and evaporated under vacuum using a water bath temperature of 40 ± 10°C until no more solvent distilled. The reactor was cleaned and dried.

[00112] The second portion of compound 9 and compound 11 were charged to the reactor and treated identically to first batch. Following organic extraction of the second batch, the reaction mixtures were combined in the reactor. A portion of sodium chloride solution was charged to the reactor and mixed thoroughly. Silica gel (1700 g) was charged to a Büchi bowl and fitted to a rotavapor. The bottom layer in the reactor was charged to the Büchi and evaporated under vacuum using a water bath temperature of 40 ± 10°C until no more solvent distilled. The bowl contents were divided into two portions purified independently on silica gel. A 150 L KP-SIL cartridge was installed in the Biotage system (commercially available from Biotage, a division of Dyax Corporation, Charlottesville, Virginia, USA). Ethyl acetate (7.7 kg) and petroleum ether (22.0 kg) were charged to the 50 L reactor, mixed thoroughly and then transferred to two Biotage solvent reservoirs. The solvent reservoirs contents were eluted through the column so as to condition the column. The eluent was collected in 20 L jerry cans and discarded. A portion of the dry load silica from above was charged to the Biotage Sample-Injection Module (SIM) and then eluted with the ethyl acetate/petroleum ether as follows:

[00113] Ethyl acetate (1.5 kg) and Petroleum ether (4.4 kg) were charged to a HDPE jerry can, mixed thoroughly and then transferred to a Biotage solvent reservoir. Column run-off was collected in 20 L jerry cans. [L SEP]

[00114] Ethyl acetate (18.6 kg) and Petroleum ether (8.8 kg) were charged to the 50 L reactor, mixed thoroughly, transferred to two Biotage solvent reservoirs and then eluted through the column. Column run-off was collected in 20 L jerry cans. [L SEP]

[00115] Ethyl acetate (19.2 kg) and Petroleum ether (8.4 kg) were charged to the 50 L reactor, mixed thoroughly, transferred to two Biotage solvent reservoirs and then eluted through the column. Column run-off was collected in 20 L jerry cans. [L SEP]

[00116] Ethyl acetate (29.7 kg) and Petroleum ether (11.9 kg) were charged to the 50 L reactor, mixed thoroughly, transferred to two Biotage solvent reservoirs and then eluted through the column. Column run-off was collected in 20 L jerry cans. [L SEP]

[00117] Ethyl acetate (15.5 kg) was charged to a Biotage solvent reservoir and then eluted through the column. Column run-off was collected in 5 L glass lab bottles.

[00118] Column fractions were sampled for product purity (TLC to identify fractions with product). Fractions that were 75 – 95 % area compound 12 from the first two columns were combined in a Büchi bowl charged with silica gel (400 g) and evaporation was run under vacuum using a water bath temperature of 40 ± 10°C until no more solvent distilled. Ethyl acetate (7.7 kg) and petroleum ether (22.0 kg) were charged to the 50 L reactor, mixed thoroughly and then transferred to two Biotage solvent reservoirs. The solvent reservoirs contents were eluted through the column so as to condition the column. The eluent was collected in 20 L jerry cans and discarded. The dry load silica containing the impure product was charged to the Biotage Sample-Injection Module (SIM) and then eluted as detailed below:

[00119] Ethyl acetate (1.5 kg) and Petroleum ether (4.4 kg) were charged to the 50 L reactor, mixed thoroughly and then transferred to a Biotage solvent reservoir. Column run-off was collected in 20 L jerry cans.

[00120] Ethyl acetate (19.2 kg) and Petroleum ether (8.4 kg) were charged to the 50 L reactor, mixed thoroughly, transferred to two Biotage solvent reservoirs and then eluted through the column. Column run-off was collected in 20 L jerry cans.

[00121] Ethyl acetate (18.6 kg) and Petroleum ether (8.8 kg) were charged to the 50 L reactor, mixed thoroughly, transferred to two Biotage solvent reservoirs and then eluted through the column. Column run-off was collected in 20 L jerry cans.

[00122] Ethyl acetate (29.7 kg) and Petroleum ether (11.9 kg) were charged to the 50 L reactor, mixed thoroughly, transferred to two Biotage solvent reservoirs and then eluted through the column. Column run-off was collected in 20 L jerry cans.

[00123] Ethyl acetate (15.5 kg) was charged to a Biotage solvent reservoir and then eluted through the column. Column run-off was collected in 5 L glass lab bottles.

[00124] Column fractions were sampled for product purity (TLC to identify fractions with product, HPLC pass criteria ≥ 95 % compound 12 and no single impurity > 2.5 %). The accepted column fraction from all three columns were combined in a Büchi

bowl and evaporation was run under vacuum using a water bath temperature of 40 ± 10 °C until no more solvent distilled. The contents of the bowl was sampled for analytical and retention. Bowl was sealed and transferred to storage at ≤ –15 °C. Expected Yield: 494 – 584 kg (52 – 64 % yield).

Synthesis of Compound 13

[00125] Glacial acetic acid (7.5 kg) and ethyl acetate (6.5 kg) were combined in a suitable container and labeled as "GAA/EA solution". Sodium bicarbonate (0.5 kg) was dissolved in RO water (10 kg) and labelled as "5% w/w sodium bicarbonate solution." Palladium on activated carbon (100g, specifically Johnson Matthey, Aliso Viejo, California, USA, Product No. A402028-10) and GAA/EA solution (335 g) was charged into a reaction vessel in that order. Compound 12 (270 g) was dissolved in GAA/EA solution (1840 g) and transferred to a 50L reaction vessel. The solution was purged of oxygen by pressurization with nitrogen to 10 bar and then released. This was repeated twice more. The reactor contents were pressurized under hydrogen to 10 bar and then released. The reaction mixture was hydrogenated at 20 bar H_2 for 1.5 days. The pressure was then released and the solution purged of hydrogen by pressurization with nitrogen to 10 bar and then release. This was repeated once. Reaction mixture was filtered through a pad of Celite (300 g). The celite cake was washed with GAA/EA solution (2 x 5.5 kg). Filtrates were combined and evaporated under vacuum (bath temperature 40 ± 5°C). The residue was co-evaporated with ethyl acetate (2.3 kg) in two portions. The expected weight of the crude product was ~316 g. A Biotage system was equipped with 150 M KP-SIL cartridge with a 5L Sample Injection Module (SIM). Ethyl acetate (10.6 kg) and glacial acetic acid (1.4 kg) were charged to the 50 L reactor, mixed thoroughly and then transferred to a Biotage solvent reservoir. The contents of the solvent reservoir were eluted through the column so as to condition the column. The eluent was discarded. The crude product was dissolved in ethyl acetate (422 g) and glacial acetic acid (55 g). The resulting solutions were charged to the SIM and passed onto the column. The reaction mixture was chromatographed as follows:

[00126] Ethyl acetate (13.8 kg) and glacial acetic acid (1.8 kg) were charged to the 50 L reactor, mixed thoroughly and then transferred to a Biotage solvent reservoir.

[00127] The contents of the solvent reservoir were eluted through the SIM onto the column and the eluent was collected in a 20 L jerry can.

[00128] Ethyl acetate (10.3 kg), glacial acetic acid (1.3 kg) and methanol (206 g) were charged to the 50 L reactor, mixed thoroughly and then transferred to a Biotage solvent reservoir.

[00129] The contents of the solvent reservoir were eluted through the column and the eluent was collected in a 5 L jerry cans.

[00130] Ethyl acetate (6.6 kg), glacial acetic acid (0.9 kg) and methanol (340 g) were charged to the 50 L reactor, mixed thoroughly and then transferred to a Biotage solvent reservoir.

[00131] The contents of the solvent reservoir were eluted through the column and the eluent was collected in ~ 2.5 L fractions in 5 L jerry cans.

[00132] Ethyl acetate (31.4 kg), glacial acetic acid (4.1 kg) and methanol (3.4 kg) were charged to the 50 L reactor, mixed thoroughly and then transferred to a Biotage solvent reservoir.

[00133] The contents of the solvent reservoir were eluted through the column and the eluent was collected in 5 L jerry cans.

[00134] Fractions containing compound 13 were combined and evaporated under vacuum (bath temperature 40 ± 5°C). Residue was dissolved in ethyl acetate (3.1 kg) and washed with 5% w/w sodium bicarbonate solution (9.3 kg), ensuring the pH of the aqueous medium was ≥ 8. The ethyl acetate phase was evaporated under vacuum (bath temperature 40 ± 5°C). The contents of the bowl was sampled for analytical and retention. Expected Yield: 182 – 207 g (71 – 81%).

Synthesis of Compound 16

[00135] Dry dichloromethane (2.5 kg) was charged to a Büchi bowl containing compound 13 (211 g, 76.5 mmol, 1.00 eq.) and rotated without heating until dissolved. A solution of (2,5-dioxopyrrolidin-1-yl) 4-acetylsulfanylbutanoate (25.8 g, 99.4 mmol, 1.30 equiv) in dry dichloromethane (200 g) was added to the Büchi bowl. The bowl was

rotated for 1 hr at ambient temperature followed by concentration under vacuum with a water bath temperature of 40 ± 5 °C. Toluene (0.8 kg) was added to the bowl and removed under vacuum with a water bath temperature of 40 ± 5°C twice. Toluene (0.8 kg) was added to the residue to dissolve. Silica gel (557 g) was loaded into the reaction vessel and solvents were removed under vacuum with a water bath temperature of 40 ± 5 °C. A Biotage system was equipped with a 150 M KP- SIL cartridge with a 5L Sample Injection Module (SIM). Toluene (10.1 kg) and acetone (1.0 kg) were charged to the 50 L reactor, mixed thoroughly and then transferred to a Biotage solvent reservoir (Solvent A). The reaction mixture was purified as follows:

[00136] Solvent A was eluted through the column so as to condition the column. The eluent was discarded.

[00137] Dry loaded silica gel was transferred to the SIM.

[00138] Toluene (9.6 kg) and acetone (1.5 kg) were charged to the 50 L reactor, mixed thoroughly and then transferred to a Biotage solvent reservoir (Solvent B).

[00139] Solvent B was eluted through the column and the eluent was collected in 5 L jerry cans.

[00140] Toluene (53.6 kg) and acetone (12.2 kg) were charged to the 50 L reactor, mixed thoroughly and then transferred to Biotage solvent reservoirs (Solvent C).

[00141] Solvent C was eluted through the column and the eluent is collected in 5 L jerry cans.

[00142] Toluene (8.4 kg) and acetone (2.6 kg) were charged to the 50 L reactor, mixed thoroughly and then transferred to a Biotage solvent reservoir (Solvent D).

[00143] Solvent D was eluted through the column and the eluent was collected in a 5 L jerry cans.

[00144] Toluene (23.4 kg) and acetone (9.2 kg) were charged to the 50 L reactor, mixed thoroughly and then transferred to a Biotage solvent reservoir (Solvent E).

[00145] Solvent E was eluted through the column and the eluent was collected in a 5 L jerry cans. [L SEP]

[00146] Fractions containing compound 16 (pass criteria ≥ 90 % compound 16 and no single impurity > 2.5 %) were combined and evaporated under vacuum (bath temperature 40 ± 5°C). The residue was dissolved in tetrahydrofuran (4.4 kg) and concentrated under vacuum with a water bath temperature of 40 ± 5 °C. The contents of the bowl were sampled for analytical and retention. Expected Yield: 169 – 192 g (76 – 86%).

Synthesis of Compound 17

[00147] The reactor was marked at the 2.5L, 3.5L and 3.9 L levels before starting and fit with a vacuum controller. Dichloromethane was charged to a Büchi Bowl containing 140 g of compound 16 and transferred to the Reactor Ready vessel. Two rinses of DCM (333 g) were used to transfer the contents of the Büchi bowl into the Reactor Ready vessel. Ethanol (2.50 kg) was added to the reactor ready. The reaction mixture was concentrated to the 2.5 L mark (target vacuum 250 mbar). Ethanol (1.58 kg) was added to the reactor ready and concentrated to the 3.5 L mark. The reaction was diluted to the 3.9 L mark with ethanol. Reactor contents were placed under inert gas by applying a partial vacuum and releasing with nitrogen. A slow flow of nitrogen was maintained during the reaction. Hydrazine monohydrate (1.13 kg, 1.11 L) was charged to the 5L Reactor Ready vessel under a nitrogen atmosphere. The temperature ramp was set to: initial temp 20°C, final temp 60°C, with a linear temperature ramp over 50 min (0.8 deg/min) and active control on the contents of the reactor. The vessel temperature was held at 60 °C for 45 min. The cooling ramp temperature was set to: -2 deg/min, with the final temp 20 °C. The contents were discharged to suitable HDPE jugs and weights determined. Equal amounts were transferred to 8 polypropylene centrifuge containers with FEP encapsulated seals. Each centrifuge container was charged with ethanol (750 g) and agitated for 30 min at ambient. The containers were centrifuged (5300 RCF, 15°C, 30 min). Residual hydrazine on the outside of the containers was removed by rinsing the outside of the bottles with acetone then water before taking out of fume hood. The supernatant in the centrifuge containers was decanted and the residual pellet was dissolved in Low Endotoxin water (LE water) (1960 g) and transferred to a 5 L Reactor

Ready vessel. The contents were agitated at medium speed while bubbling air through the solution using a dispersion tube approximately 15-20 min for every 1.5 hrs. The reaction was then stirred overnight at 20 °C in a closed vessel. Once IPC indicated free pentamer composition was below 3% (area % of the total reported) the reaction was considered complete. Filtration (using a P3 sintered glass funnel and 5 L Buchner flask) was required if there were any insoluble material present in reaction mixture. Contents of the reactor were freeze-dried in 2 Lyoguard trays. The shelf temperature was set at –0.5 °C for 16-20 h and then at 20 °C until dry. Freeze- dried product was dissolved in LE water (840 g) and divide equally between 6 centrifuge bottles. Acetone (630 g) was added to each container agitated for 15 minutes. Isopropanol (630 g per container) was added to each container and agitation continued for 20 min. Contents were centrifuged at 5300 RCF at 15°C, for 1 h. The supernatants were discarded and each pellet was dissolved in water by adding LE water (140 g) to each container and then agitating the mixture at ambient using an orbital shaker until the pellets dissolved. Acetone (630 g) was added to each container and agitated for 15 minutes. Isopropanol (630 g per container) was added to each container and agitation continued for 20 min. The contents were centrifuged at 5300 RCF at 15°C, for 1 h. The supernatants were discarded and each pellet was dissolved in water by adding LE water (100 g) followed by agitation at ambient. The solutions were transferred to a Lyoguard tray and bottles were rinsed with more LE water (66 g each) and the rinses were transferred to the same tray. The product was freeze-dried by setting the shelf temperature at –0.5 °C for 16-20 h and then at 20 °C until dry. Freeze-dried product was sampled for analytical and retention. The Lyoguard Tray was double-bagged, labelled and stored in the freezer (≤ –15 °C). The potency of freeze-dried product was determined using qHNMR. This procedure afforded Crude Penta Dimer 17. Expected Yield: 26.1 – 35.5 g (61 – 83 %).

[00148] The identity of the compound 17 was determined by ^{1}H and ^{13}C NMR using a 500 MHz instrument. A reference solution of *t*-butanol was prepared at 25 mg/mL in D_2O. Samples were prepared at 13 mg/mL in D_2O and the reference solution is added to the sample. The composition of the final test sample was 10 mg/mL of the Penta Dimer and 5 mg/mL of *t*-butanol. The ^{1}H and ^{13}C spectra were acquired and integrated. The resulting chemical shifts were assigned by comparison to theoretical shifts. The ^{1}H NMR and ^{13}C NMR spectra are shown in Figures 1 and 2 respectively.

Example 5 - Conversion of Crude Penta Dimer to Free Base Form.

[00149] Amberlite FPA91 (1.46 kg; 40 g/g of Crude Penta Dimer - corrected for potency) was charged to a large column. A solution of 8 L of 1.0 M NaOH was prepared by adding NaOH (320 g) to LE water (8.00 kg) in a 10 L Schott Bottle. This solution was passed through Amberlite resin over a period of 1 hour. LE water (40.0 kg) was passed through the Amberlite resin. The resin was flushed with additional LE water (~10 kg aliquots) until a pH of < 8.0 was attained in the flow-through. The crude Penta Dimer (49 g, PN0704), stored in a Lyoguard tray, was allowed to warm to ambient temperature. LE water (400 g) was added to the Lyoguard tray containing Crude Penta Dimer (49 g) and allowed to fully dissolve before transferring to a 1 L Schott bottle. The tray was rinsed with a further charge of LE water (200 g) and these washings were added to the Schott bottle contents. The Crude Penta Dimer solution was carefully poured onto the top of the resin. The 1 L Schott bottle was rinsed with LE water (200 g) and loaded this onto the resin. The Amberlite tap was opened to allow the Crude Penta Dimer solution to move slowly into the resin over ~5 min. The tap was stopped and material left on the resin for ~10 min. LE water was poured onto the top of the resin. The tap was opened and eluted with LE water, collecting approximately 16 fractions of 500 mL. Each fraction was analyzed by TLC charring (10% H_2SO_4 in EtOH). All carbohydrate containing fractions were combined and filtered through a Millipore filter using a 0.2 µm nylon filter membrane. The solution was divided equally between 5 – 6 Lyoguard trays. The filtration vessel was rinsed with LE water (100 g) and divided between the trays. The material was freeze dried in the trays. The shelf temperature was set at –10°C for 16-20 hr and then at +10 °C until the material was dry. LE water (150 g) was charged to all but one of the Lyoguard trays and transferred this into the one remaining tray containing dried material. Each of the empty trays was rinsed with a further charge of LE water (100 g) and this rinse volume was added to the final Lyoguard tray. The final Lyoguard tray was freeze dried. The shelf temperature was set at – 10°C for 16-20 hr and then at +10°C until the materials dry. The product was sampled for analytical and retention. Dried material was transferred to HDPE or PP containers and stored at ≤ -15°C. Expected yield: 31 – 34 g (86 – 94 %).

[00150] TCEP reduction of the disulfide bond in the dimer is rapid and nearly stoichiometric. Use of a stoichiometric reduction with TCEP afforded approximately 2

equivalents of glucosamine pentasaccharide monomer. Specifically, the pentasaccharide dimer was dissolved in reaction buffer (50 mM HEPES buffer (pH 8.0)) containing 1 molar equivalent of TCEP. After 1 hour at ambient temperature, the reaction was analyzed by HPLC with CAD detection. Under these conditions, conversion to the penta-glucosamine monomer (peak at ~ 10 minutes) was nearly complete (penta glucsamine dimer peak at ~ 11.5 minutes) – See Figure 4. The remaining unannotated peaks were derived from the sample matrix. Based on the balanced chemical equation, the added TCEP was largely converted to TCEP oxide and any residual TCEP inhibited air oxidation back to the dimer prior to addition to the conjugation reaction. For simplicity, glucosamine pentasaccharide can be added based on input dimer and assuming >95% conversion to the monomer under these conditions.

[00151] The identity of the Penta Dimer was determined by ^{1}H and ^{13}C NMR using a 500 MHz instrument. A reference solution of *t*-butanol was prepared at 25 mg/mL in D_2O. Samples were prepared at 13 mg/mL in D_2O and the reference solution was added to the sample. The composition of the final test sample was 10 mg/mL of the Penta Dimer and 5 mg/mL of *t*-butanol. The ^{1}H and ^{13}C spectra were acquired and integrated. The resulting chemical shifts are assigned by comparison to theoretical shifts. ^{1}H and ^{13}C NMR spectra are shown in Figures 1 and 2 respectively.

Example 5 - Conversion to the Penta Saccharide Monomer of Example 4 with the TT-Linker of Example 2 to provide for a Vaccine of this invention (compound 18)

[00152] The TT monomer-linker intermediate of Example 2 was reacted with increasing concentrations of 4 – 70 pentameric glucosamine molar equivalents (2-35 pentasaccharide dimer molar equivalents) for 4 hours at ambient temperature. The crude conjugates from each titration point were purified by partitioning through a 30 kDa MWCO membrane. Each purified conjugate sample was analyzed for protein content, payload density by SEC-MALS and monomer / aggregate content by SEC HPLC. The data showed saturation of the payload density at ≥ 50 pentameric glucosamine equivalents. Based on the SEC HPLC analysis, the aggregate content increased as the pentasaccharide monomer charge was increased and appeared to reach steady state levels of an approximately 4 % increase starting at 30 pentameric glucosamine equivalents. Based on these results, the pentasaccharide dimer charge selected for subsequent conjugation

reactions was 25 molar equivalents, corresponding to a theoretical charge of 50 molar equivalents of pentameric glucosamine.

[00153] A series of three trial syntheses followed by a GMP synthesis of compound 18 were prepared as per above. Each of the resulting products was evaluated for potency (by ELISA assay) and payload density (molar ratio of pentameric glucosamine to tetanus toxoid). The following table provides the results.

	Trial No. 1	Trial No. 2	Trial No. 3	GMP Run
Payload Density of Compound 18	35	38	36	35
Potency of Compound 18	94%	101%	87%	98%

[00154] These results evidence very high loading factors for the compounds of this invention. The foregoing description has been set forth merely to illustrate the invention and is not meant to be limiting. Since modifications of the described embodiments incorporating the spirit and the substance of the invention may occur to persons skilled in the art, the invention should be construed broadly to include all variations within the scope of the claims and equivalents thereof.

Example 6 – Monoclonal Antibody F-598

[00155] The monoclonal antibody designated as F-598 is disclosed in US Patent No. 7,786,255 which is incorporated herein by reference in its entirety. It is also commercially available from Creative Biolabs, Shirley, New York, USA as TAB-799CL and AFC-765CL. The amino acid sequence for F-598 is provided in SEQ ID Nos. 1-5.

Example 7 – 45 year old, 175 lb firefighter with burns over 45% of his body

[00156] The patient is immediately identified as having a high risk of developing sepsis. To minimize that risk, the patient is first administered a therapeutic dose of monoclonal antibody (mAb) F-598. This antibody imparts immediate immune therapy for the patient. Approximately 2 hours later, the patient is administered a vaccine of formula I as disclosed herein.


[00157] The patient is monitored to ensure that therapeutic levels of the monoclonal and polyclonal antibody remain in the patient's serum. As necessary, additional treatments of the monoclonal antibody are administered to ensure that a therapeutic serum concentration is maintained. Likewise, the polyclonal antibody titer generated by the compounds described herein is measured. As necessary, additional vaccine can be administered to the patient to ensure that a therapeutic serum concentration is maintained. Therapy is continued until the patient is no longer at such risk.

WHAT IS CLAIMED IS:

1. A method of providing continuous protection against microbial infection, which method comprises administering to said patient a therapeutically effective amount of a monoclonal antibody F-598 and a vaccine of formula I:

$$(A\text{-}B)_x\text{-}C \quad I$$

wherein A comprises 3 to 12 β-(1→6)-glucosamine (carbohydrate ligand) groups or mixtures thereof wherein said oligosaccharide portion of the vaccine is represented by formula A:



B is a linker ;

where A is as defined above and C is tetatus toxoid;

x is an integer from about 30 to about 39; and

y is an integer from 1 to 10.

2. The method of claim 1, wherein the vaccine of formula I is administered concurrently with F-598.


3. The method of claim 1, wherein the vaccine of formula I is administered within about 6 hours of administering F-598.

4. The method of claim 1, wherein the vaccine of formula I is administered within about 4 hours of administering F-598.

5. The method of claim 1, wherein the vaccine of formula I is administered within about 2 hours of administering F-598.

6. The method of claim 1, wherein F-598 is co-administered during an entire treatment period.

7. The method of claim 1, wherein the linker is represented by the formula:



where A and C are not included within the linker.


8. The method of claim 1, wherein F-598 is co-administered up until a point where sufficient antibody titer is produced by the vaccine of formula I to effectively treat the patient.

9. A method for providing effective immunity to a subject from microbes comprising oligosaccharide β-(1→6)-glucosamine groups in their cell wall which method comprises administering the vaccine of claim 7 to said subject.

10. A method of inhibiting biofilm formation comprising administering to a patient a therapeutically effective amount of a monoclonal antibody F-598 and a vaccine of formula I:

$$(A\text{-}B)_x\text{-}C \qquad I$$

wherein A comprises 3 to 12 β-(1→6)-glucosamine (carbohydrate ligand) groups or mixtures thereof wherein said oligosaccharide portion of the vaccine is represented by formula A:



B is a linker ;

where A is as defined above and C is tetatus toxoid;

x is an integer from about 30 to about 39; and

y is an integer from 1 to 10.

11. The method of claim 10, wherein the vaccine of formula I is administered concurrently with F-598.


12. The method of claim 10, wherein the vaccine of formula I is administered within about 6 hours of administering F-598.

13. The method of claim 10, wherein the vaccine of formula I is administered within about 4 hours of administering F-598.

14. The method of claim 10, wherein the vaccine of formula I is administered within about 2 hours of administering F-598.

15. The method of claim 10, wherein F-598 is co-administered during an entire treatment period.


16. The method of claim 10, wherein the linker is represented by the formula:



where A and C are not included within the linker.

17. The method of claim 10, wherein F-598 is co-administered up until a point where sufficient antibody titer is produced by the vaccine of formula I to effectively treat the patient.

18. A method for providing effective protection against biofilm formed by microbes comprising oligosaccharide β-(1→6)-glucosamine groups in their cell wall which method comprises administering the vaccine of claim 16 to said subject.



^{1}H NMR Spectrum of the Penta

FIG. 1




FIG. 2

^{13}C NMR Spectrum of the Penta Dimer

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 20/61594

A. CLASSIFICATION OF SUBJECT MATTER

IPC - A61K 39/02; A61K 39/08; A61K 39/395; A61K 47/36 (2021.01)

CPC - A61K 39/02; A61K 39/08; A61K 39/395; A61K 47/36; A61K 47/6415

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 10,034,927 B2 (The Brigham and Women's Hospital, Inc.) 31 July 2018 (31.07.2018) Col 2, ln 10-13; Col 5, ln 65 to Col 6, ln 2 ;Col. 6, ln 24-25; Col 8, ln 17-22 ; Col 14, ln 1-17; Col 15, ln 5 -20; Col 19, ln 40-44; Col. 23, first structure; Col 29, Scheme 6; Col 30, ln 66-67;Col 32, ln 46-52	1-18
Y	ALOPEXX Pharmaceuticals, LLC. 'Antibody Targeting of Poly N-acetyl Glucosamine (PNAG), A conserved surface polysaccharide on Multiple microbial pathogens, Potential as a broad-spectrum biological therapeutic', Presentation presented at PAHO, World Health Organization, Washington, D.C., 14 November 2014. pg. 1-22. Downloaded from: https://www.alopexx.com; pg. 2; pg.12; pg. 13; pg. 21	1-18
A	WO 2011/133227 A2 (ANCORA PHARMACEUTICALS INC.) 27 October 2011 (27.10.2011) ENIRE DOCUMENT	1-18
A	US 2006/0115486 A1 (PIER et al.) 01 June 2006 (01.06.2006) ENTIRE DOCUMENT	1-18

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"D" document cited by the applicant in the international application
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
25 January 2021	APR 05 2021
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-8300	Authorized officer Lee Young Telephone No. PCT Helpdesk: 571-272-4300